BXBufang Xu

Bufang Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bufang Xu has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Aijun Zhang

    Department of Reproductive Medical Center, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    20 shared publications
  • Dan Zhang

    Department of Obstetrics and Gynecology of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    14 shared publications
  • Mingjuan Zhou

    Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    12 shared publications
  • Xiaowei Zhou

    Department of Obstetrics and Gynecology of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    11 shared publications
  • Huihui Xu

    Shanghai Jiao Tong University School of Medicine

    7 shared publications
  • Mengyu Liu

    Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    7 shared publications

Latest Publications

  • Open Access

    Single-cell transcriptomic landscape of the mid-secretory eutopic endometrium reveals receptivity defects in adenomyosis

    by Yan Zhou, Chenjia He, Meihan Xu, Juan Huang, Yang Hu, Wenjie Zhou, Xiaowei Zhou, Hanfei Zhu, Yuyang Liu, Dan Zhang, et al.

    Adenomyosis (AM) is a common gynecological disorder in reproductive-age women, with impaired endometrial receptivity as a key contributor to infertility. H

  • Increased AIF-1-mediated p38 MAPK phosphorylation in the mid-secretory endometrium impairs endometrial receptivity in women with recurrent implantation failure

    by Mingjuan Zhou, Jingru Duan, Xiaowei Zhou, Hanfei Zhu, Dan Zhang, Bufang Xu, Aijun Zhang

    STUDY QUESTION: How does allograft inflammatory factor-1 (AIF-1) affect endometrial receptivity in women with recurrent implantation failure (RIF)? SUMMARY ANSWER: Significant upregulation of AIF-1 in the endometrial stromal cells of women with RIF inhibits cell proliferation and decidualization via the p38 mitogen-activated protein kinase (MAPK) phosphorylation, thereby reducing endometrial receptivity. WHAT IS KNOWN ALREADY: RIF is a challenging clinical issue, with AIF-1, a cytokine-inducible protein linked to allograft rejection, potentially contributing to its pathogenesis. However, the precise mechanisms remain elusive. STUDY DESIGN, SIZE, DURATION: This study analyzed endometrial tissue samples from women diagnosed with RIF and a control group of fertile women from December 2018 to December 2023. Single-cell RNA sequencing (scRNA-seq) data from public datasets (GSE111976, GSE250130, GSE183837) were integrated to characterize AIF-1 expression patterns in endometrium. Isolated human endometrial stromal cells (HESCs) from the human endometrium and an endometrial stromal cell line were used for in vitro analysis, and an in vivo mouse model with AIF-1 overexpression in the uterus was employed to evaluate implantation outcomes. PARTICIPANTS/MATERIALS, SETTING, METHODS: Mid-secretory endometrial samples were collected from the 18 patients with RIF and 18 control patients; endometrial samples from another five different phases during the menstrual cycle were collected from 30 additional control patients. Quantitative PCR, western blot, immunohistochemical and immunofluorescence analyses, and RNA sequencing were conducted to determine the expression levels of AIF-1 and various markers. Cell proliferation, decidualization, and trophoblast outgrowth were measured. AIF-1 overexpression and gene silencing were achieved by plasmid injection and short hairpin RNA, respectively. For in vivo experiments, CD-1 mice with intrauterine injection of an AIF-1 plasmid were used. Phosphorylation of p38 was inhibited by PD169316. MAIN RESULTS AND THE ROLE OF CHANCE: Based on scRNA-seq analysis and our own endometrial tissue detection, AIF-1 was significantly increased in HESCs in patients with RIF compared with their control group during the mid-secretory phase. AIF-1 overexpression resulted in reduced cell proliferation, inadequate cell decidualization, and diminished embryo outgrowth in in vitro experiments, and it reduced the number of embryo implantation sites in CD-1 mice; these effects were mitigated by PD169316, an inhibitor of p38 MAPK. LIMITATIONS, REASONS FOR CAUTION: Although the study establishes a link between increased AIF-1 expression in endometrial stromal cells and reduced endometrial receptivity, the role of AIF-1 in endometrial macrophages during embryo implantation remains unclear. WIDER IMPLICATIONS OF THE FINDINGS: The findings suggest that targeting the AIF-1 and p38 MAPK pathway could serve as a promising therapeutic strategy to improve endometrial receptivity in RIF patients. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Key R&D Program of China (No. 2022YFC2703800) and the National Natural Science Foundation of China [Nos. 82271703; 82371704; 82071596; 82071712; 82101800; 81701513]. The authors declare that they have no conflict of interests with the contents of this manuscript. TRIAL REGISTRATION NUMBER: N/A.


  • Injectable self-expanding short-fiber scaffold reduces endometrial hyperplasia

    by Yan Zhou, Mingyue Liu, Jingru Duan, Chenjia He, Meihan Xu, Juan Huang, Aijun Zhang, Wenguo Cui, Bufang Xu


  • Open Access

    Granulosa cell-specific FOXJ2 overexpression induces premature ovarian insufficiency by triggering apoptosis via mitochondrial calcium overload

    by Yunxia Zhang, Qiqian Wu, Furong Bai, Yanqin Hu, Bufang Xu, Yujie Tang, Jingwen Wu

    Follicle development is a complicated biological process that produces mature oocytes, and requires nutrients, growth factors, and steroids produced by ovarian granulosa cells (GCs). High fork head box J2 (FOXJ2) expression might negatively regulate ovarian function; however, the mechanism is unclear. This study aimed to investigate the effect and mechanism of FOXJ2 overexpression in GCs on regulating follicle development and fertility. A GC-specific conditional Foxj2 knock-in mouse model (Amh-cre; Foxj2tg/tg mouse) was generated. Reproductive phenotypes were compared between Amh-cre; Foxj2tg/tg and control mice using fertility evaluation, oocyte collection, estrus cycle analysis, hormone evaluation, and ovarian follicle assessment. Then, RNA sequencing and bioinformatic analyses were used to detect the altered transcriptome of GCs collected from the Amh-cre; Foxj2tg/tg and wild-type mice. Western blotting, transmission electron microscopy, immunofluorescence staining, and flow cytometry were used to explore apoptosis and mitochondrial calcium homeostasis. Furthermore, Chromatin immunoprecipitation-PCR and dual-luciferase reporter assays were used to detect the target gene of FOXJ2. Moreover, short hairpin RNA interference was performed on primary GCs and human ovarian granulosa-like tumor (KGN) cells to explore the relationship between FOXJ2 and its target gene in apoptosis and mitochondrial calcium overload. FOXJ2 overexpression in GCs led to reduced fertility, hormonal abnormalities, and follicle atresia, starting at the initiation of sexual maturity, resulting in a premature ovarian insufficiency (POI)-like phenotype. Increased apoptosis and mitochondrial calcium overload were detected in the GCs of Amh-cre; Foxj2tg/tg mice. Mcu (encoding a mitochondrial calcium uniporter) was observed to be upregulated in the GCs of the Amh-cre; Foxj2tg/tg mice and was a direct target of FOXJ2. Moreover, Mcu knockdown restored mitochondrial calcium homeostasis and reduced the apoptosis in the GCs of the Amh-cre; Foxj2tg/tg mice and in KGN cells transfected with FOXJ2-overexpression lentivirus.


  • Open Access

    Decreased expression of LEF1 caused defective decidualization by inhibiting IL-11 expression in patients with adenomyosis

    by Jingru Duan, Xiaowei Zhou, Hanfei Zhu, Mingjuan Zhou, Mengyu Liu, Yan Zhou, Wenzhu Li, Bufang Xu, Aijun Zhang

    Reduced lymphoid enhancer-binding factor 1 (LEF1) expression in patients with adenomyosis during the mid-secretory phase leads to impaired endometrial receptivity, affecting embryo implantation. This study investigated the molecular mechanisms underlying reduced endometrial receptivity in 25 adenomyosis patients and 25 controls. Functional experiments were conducted using human endometrial stromal cells (HESCs) and TERT-immortalized HESCs(T-HESCs), with final validation performed using a mouse model. Western blot and quantitative real-time polymerase chain reaction (RT-qPCR) analyses revealed that patients with adenomyosis showed a marked decrease in LEF1 expression in the stromal cells of the endometrium during the mid-secretory phase. In vitro experiments demonstrated that LEF1 knockdown in stromal cells led to impaired decidualization. Transcriptome sequencing, dual-luciferase reporter assays, and chromatin immunoprecipitation (ChIP) experiments showed that LEF1 could bind to the promoter region of interleukin (IL)-11 and promote its transcription, and IL-11 expression was also found to be downregulated in adenomyosis patients. Overexpression of IL-11 rescued the impaired decidualization caused by decreased LEF1 expression. In the in vitro co-culture model, LEF1/IL-11 knockdown led to a reduction in embryo implantation area, which was partially restored upon IL-11 overexpression. In the adenomyosis mouse model, we observed a decrease in LEF1 expression and a reduction in implantation sites compared to control mice, accompanied by impaired decidualization and receptivity. Notably, supplementation with IL-11 restored the number of implantation sites. The decrease in fertility due to reduced endometrial receptivity in adenomyosis patients is a significant clinical issue in assisted reproductive technology. This research provides insights into one potential molecular mechanism underlying this decreased receptivity, with a specific focus on the reduced expression of LEF1 in the endometrial stromal cells during the mid-secretory phase in adenomyosis patients. Our findings offer new perspectives for clinical strategies to improve endometrial receptivity in patients with adenomyosis, potentially enhancing their chances of successful pregnancy.


  • Open Access

    WITHDRAWN: Prednisone enhances pregnancy outcomes in gonadotropin-releasing hormone antagonist protocol: a multi-center randomized clinical trial

    by Dan Zhang, Xian Wu, Ai-Fang Jiang, Tingting Yang, Shu-Qin Zhao, Lei Wang, Jian Li, Yan Li, Xiao-Wei Zhou, Lan Xia, et al.

    Background The gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol in controlled ovarian stimulation (COS) has distinct advantages and become widespread. However, the dose-dependent disturbance of GnRH-ant on endometrial immune factors may negatively impact endometrial receptivity, potentially contributing to lower clinical pregnancy rates in fresh embryo transfer cycles, thereby diminishing the benefits of this protocol. Identifying strategies to mitigate these adverse effects on the endometrium is crucial for improving pregnancy outcomes in fresh embryo transfer cycles following this COS protocol. Prednisone, a primary immunosuppressive agent, has been proposed as a means to counteract the negative effects of GnRH-ant on the endometrium. This study designed a multi-center randomized clinical trial to compare the efficacy of combining prednisone with a fixed full-dose GnRH-ant protocol versus a flexible half-dose GnRH-ant protocol and a conventional fixed full-dose GnRH-ant protocol. Methods and Findings We conducted a randomized, controlled, open-label clinical trial across three reproductive centers in China from April 2019 to November 2022, with follow-up completed in August 2023. Of the 5,042 identified patients aged 20 to 35 years undergoing in vitro fertilization and embryo transfer (IVF-ET) with the GnRH-ant protocol, 2,052 patients without contraindications for fresh embryo transfer were enrolled. Participants were randomly assigned to three groups: Group A received a fixed full-dose GnRH-ant combined with prednisone 10 mg per day from the start day of stimulation until 11 to 14 days after embryo transfer; Group B received a flexible half-dose GnRH-ant; and Group C received a fixed full-dose GnRH-ant. The primary outcome, clinical pregnancy rate (CPR), was defined as the ultrasound confirmation of an intrauterine gestation sac 30 to 35 days after embryo transfer, divided by the number of cases that underwent transfer. Of the enrolled patients, 1,512 (73.7%) underwent embryo transfer. Group A demonstrated a significantly higher CPR (63.1%) compared to Group B (54.7%; rate difference (RD) 8.4%, 95% confidence interval (CI) 2.4%–14.5%, P = 0.007) and Group C (46.4%; RD 16.7%, 95% CI 10.7%–22.7%, P < 0.001). The cancellation rate of fresh embryo transfer in Group A (18.7%) was similar to that in Group C (19.9%), but significantly lower than in Group B (24.1%). No significant differences in embryo laboratory results or in adverse events were observed among the groups. Conclusions In patients undergoing IVF with the GnRH-ant protocol, the addition of low dose prednisone significantly improved the CPR without increasing adverse effects. These findings suggest an optimal strategy to enhance the success of the antagonist protocol in IVF-ET. Trial registration Chinese clinical trial registry: ChiCTR1900021024.


  • Open Access

    The Superiority and Feasibility of Fresh Single Blastocyst Transfer in the Gonadotropin-Releasing Hormone Antagonist Protocol

    by Huihui Xu, Shen Zhao, Hsun-Ming Chang, Weimin Fan, Xian Wu, Lan Xia, Xiaowei Zhou, Jian Li, Aijun Zhang, Bufang Xu

  • Open Access

    Downregulation of SEPTIN11 inhibits endometrial epithelial cell adhesive function in patients with elevated peripheral blood natural killer cell counts

    by Wenzhu Li, Mengyu Liu, Mingjuan Zhou, Xiaowei Zhou, Dan Zhang, Jingru Duan, Aijun Zhang, Bufang Xu


  • Open Access

    The serum follicle stimulating hormone-to-luteinizing hormone ratios can predict assisted reproductive technology outcomes in women undergoing gonadotropin releasing hormone antagonist protocol

    by Shen Zhao, Huihui Xu, Xian Wu, Lan Xia, Jian Li, Dan Zhang, Aijun Zhang, Bufang Xu

    Background: The basal follicle stimulating hormone (FSH)/luteinizing hormone (LH) ratio is a useful predictor of ovarian response. In this study, we investigated whether the FSH/LH ratios during the entire controlled ovarian stimulation (COS) can be used as effective predictors of outcomes in women undergoing in vitro fertilization (IVF) treatment using the gonadotropin releasing hormone antagonist (GnRH-ant) protocol.Methods: A total of 1,681 women undergoing their first GnRH-ant protocol were enrolled in this retrospective cohort study. A Poisson regression model was used to analyze the association between the FSH/LH ratios during COS and embryological outcomes. Receiver operating characteristic analysis was performed to determine the optimal cutoff values for poor responders (≤ 5 oocytes) or poor reproductive potential (≤ 3 available embryos). A nomogram model was constructed to provide a tool for predicting the cycle outcomes of individual IVF treatments.Results: The FSH/LH ratios (at the basal day, stimulation day 6 (SD6) and trigger day) were significantly correlated with the embryological outcomes. The basal FSH/LH ratio was the most reliable predictor of poor responders with a cutoff value of 1.875 (area under the curve (AUC) = 72.3%, P < 0.05), or of poor reproductive potential with a cutoff value of 2.515 (AUC = 66.3%, P < 0.05). The SD6 FSH/LH ratio predicted poor reproductive potential with a cutoff value of 4.14 (AUC = 63.8%, P < 0.05). The trigger day FSH/LH ratio predicted poor responders with a cutoff value of 9.665 (AUC = 63.1%, P < 0.05). The basal FSH/LH ratio, combined with the SD6 and trigger day FSH/LH ratios, slightly increased these AUC values and improved the prediction sensitivity. The nomogram provides a reliable model with which to assess the risk of poor response or poor reproductive potential directly based on the combined indicators.Conclusions: FSH/LH ratios are useful predictors of poor ovarian response or reproductive potential throughout the entire COS with the GnRH antagonist protocol. Our findings also provide insights into the potential for LH supplementation and regimen adjustment during COS to achieve improved outcomes.